{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T03:33:45Z","timestamp":1785123225936,"version":"3.55.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.leukres.2024.107531","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T04:11:37Z","timestamp":1717560697000},"page":"107531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"143","author":[{"given":"Hendrik","family":"Jestrabek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Kohlhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong-Hien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107531_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2024.107531_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.3145","article-title":"First line therapy of CLL","volume":"41","author":"Hallek","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment","volume":"1863","author":"ten Hacken","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2024.107531_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/bloodadvances.2021006941","article-title":"The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107531_bib5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","article-title":"Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression","volume":"14","author":"Galletti","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2024.107531_bib6","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2024.107531_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2014-05-577122","article-title":"Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy","volume":"124","author":"Simonetti","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071980","article-title":"Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the E\u00b5-TCL1 Transgenic Mouse Model","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2024.107531_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2012-05-431452","article-title":"Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor","volume":"121","author":"Reinart","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo","volume":"140","author":"Martines","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.leukres.2024.107531_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.leukres.2024.107531_bib15","article-title":"Role of the tumor microenvironment in CLL pathogenesis","author":"vom Stein","year":"2023","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.leukres.2024.107531_bib16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41467-023-36824-2","article-title":"LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1","volume":"14","author":"vom Stein","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2024.107531_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2024.107531_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3109\/10428194.2011.568078","article-title":"Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia","volume":"52","author":"Ysebaert","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107531_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bcmd.2012.12.003","article-title":"Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?","volume":"50","author":"Filip","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.leukres.2024.107531_bib20","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib22","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood-2013-10-529610","article-title":"Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia","volume":"123","author":"Jia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2011.08747.x","article-title":"Nurse-like cells show deregulated expression of genes involved in immunocompetence","volume":"154","author":"Bhattacharya","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107531_bib24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4049\/jimmunol.2100931","article-title":"Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia","volume":"209","author":"Merchand-Reyes","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/leu.2012.315","article-title":"Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1","volume":"27","author":"Croci","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3324\/haematol.2013.091405","article-title":"Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages","volume":"99","author":"Giannoni","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/onc.2017.365","article-title":"Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis","volume":"37","author":"Abbaci","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2024.107531_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69307-1","article-title":"BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells","volume":"10","author":"Talbot","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2024.107531_bib30","doi-asserted-by":"crossref","first-page":"52225","DOI":"10.18632\/oncotarget.13660","article-title":"Nurse-like cells promote CLL survival through LFA-3\/CD2 interactions","volume":"8","author":"Boissard","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2024.107531_bib31","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/bloodadvances.2021006169","article-title":"Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21","volume":"6","author":"Zaaboub","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107531_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107531_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib34","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib35","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2024.107531_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.3145","article-title":"First line therapy of CLL","volume":"41","author":"Hallek","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib40","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"Herman","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood.2020009165","article-title":"MARCKS affects cell motility and response to BTK inhibitors in CLL","volume":"138","author":"Beckmann","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib42","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282466","article-title":"Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia","author":"Rey-Barroso","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib43","first-page":"1","article-title":"Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL)","author":"Odetola","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2024.107531_bib44","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib45","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.25480","article-title":"Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group","volume":"94","author":"Quinquenel","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107531_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.leukres.2024.107531_bib47","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107531_bib48","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2024.107531_bib49","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"B\u00fcrkle","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-022-01366-5","article-title":"CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression","volume":"15","author":"Beider","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib51","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.18632\/oncotarget.26744","article-title":"Monocyte-to-macrophage switch reversibly impaired by Ibrutinib","volume":"10","author":"Ferrarini","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2024.107531_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.108","article-title":"Nurse-like cells impact on disease progression in chronic lymphocytic leukemia","volume":"6","author":"Boissard","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107531_bib53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107531_bib54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41375-018-0366-8","article-title":"New roles for B cell receptor associated kinases: when the B cell is not the target","volume":"33","author":"Nguyen","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.74","article-title":"Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients","volume":"5","author":"Boissard","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107531_bib56","doi-asserted-by":"crossref","first-page":"65968","DOI":"10.18632\/oncotarget.11782","article-title":"Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia","volume":"7","author":"Fiorcari","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2024.107531_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085834","article-title":"Btk regulates macrophage polarization in response to lipopolysaccharide","volume":"9","author":"N\u00ed Gabhann","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2024.107531_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109138","article-title":"Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization","volume":"111","author":"Li","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.leukres.2024.107531_bib59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41375-019-0556-z","article-title":"PI3K-p110\u03b4 contributes to antibody responses by macrophages in chronic lymphocytic leukemia","volume":"34","author":"Enya Chen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib60","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060476","article-title":"The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection","volume":"8","author":"K\u00f6pr\u00fcl\u00fc","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2024.107531_bib62","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","article-title":"Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages","volume":"100","author":"Borge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib63","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1074\/jbc.M115.687251","article-title":"Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc\u03b3 Receptor (Fc\u03b3R) Function","volume":"291","author":"Ren","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2024.107531_bib64","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib65","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib66","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib68","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","article-title":"Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies","volume":"6","author":"VanDerMeid","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.leukres.2024.107531_bib69","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107531_bib70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","article-title":"Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis","volume":"181","author":"Jongstra-Bilen","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082303","article-title":"Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2","volume":"12","author":"Barbarino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2024.107531_bib73","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood-2019-124901","article-title":"Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice","volume":"134","author":"Chu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib74","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.leukres.2024.107531_bib75","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V73.5.1242.1242","article-title":"Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia","volume":"73","author":"Digel","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib76","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1242544","article-title":"Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia","volume":"5","author":"Cubillos-Zapata","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2024.107531_bib77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2024.107531_bib80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.leukres.2018.08.006","article-title":"Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia","volume":"72","author":"Manukyan","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2024.107531_bib81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10428199809057538","article-title":"Regulation of B-CLL apoptosis through membrane receptors and Bcl-2 family proteins","volume":"30","author":"Osorio","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107531_bib82","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib85","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib86","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib87","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib88","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2024.107531_bib89","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib90","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hon.3009","article-title":"Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma","volume":"40","author":"Li","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib91","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","article-title":"Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis","volume":"6","author":"Vogiatzi","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107531_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax9340","article-title":"Stromal cell protein kinase C-\u03b2 inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib93","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022008207","article-title":"Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia","author":"Parvin","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107531_bib94","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3324\/haematol.2010.031377","article-title":"Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2","volume":"96","author":"Schulz","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib95","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","article-title":"Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells","volume":"17","author":"Calissano","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib96","doi-asserted-by":"crossref","unstructured":"Chen 2019_Cirmtuzumab blocks Wnt5a-ROR1 stimulation of NF-kB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.","DOI":"10.1182\/blood.2019001366"},{"key":"10.1016\/j.leukres.2024.107531_bib97","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.2019001366","article-title":"Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib98","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41420-022-00884-y","article-title":"Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia","volume":"8","author":"Guo","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.leukres.2024.107531_bib99","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.leukres.2024.107531_bib100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107531_bib101","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib102","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","article-title":"Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies","volume":"125","author":"Tipton","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib103","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib104","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib105","first-page":"2","article-title":"FDA approves new kind of lymphoma treatment. Food and Drug Administration","author":"James","year":"1997","journal-title":"AIDS Treat. N."},{"key":"10.1016\/j.leukres.2024.107531_bib106","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib107","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.leukres.2024.107531_bib108","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1634\/theoncologist.2010-0306","article-title":"U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia","volume":"16","author":"Casak","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2024.107531_bib110","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107531_bib111","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","article-title":"Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells","volume":"187","author":"Beum","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib112","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2016-08-735605","article-title":"Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies","volume":"129","author":"Valgardsdottir","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib113","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib114","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.4049\/jimmunol.181.11.8120","article-title":"Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes","volume":"181","author":"Beum","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1034\/j.1600-0609.2000.80097.x","article-title":"Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies","volume":"64","author":"Guc","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107531_bib116","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib117","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2024.107531_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1428158","article-title":"Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)","volume":"7","author":"Elias","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2024.107531_bib119","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib120","first-page":"388","article-title":"Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum","volume":"29","author":"Lefebvre","year":"2006","journal-title":"J. Immunother. (Hagerstown, Md. 1997)"},{"key":"10.1016\/j.leukres.2024.107531_bib121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cei.12697","article-title":"Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages","volume":"183","author":"Church","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib122","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2024.107531_bib123","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/onc.2016.387","article-title":"Increased Fc\u03b3RIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients","volume":"36","author":"Burgess","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2024.107531_bib124","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2018.09.007","article-title":"Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages","volume":"175","author":"Su","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2024.107531_bib125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human Fc\u03b3RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2024.107531_bib126","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1038\/s41388-020-01394-w","article-title":"HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients","volume":"39","author":"Burgess","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2024.107531_bib127","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107531_bib128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2014.113217","article-title":"Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia","volume":"100","author":"Fiorcari","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107531_bib129","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107531_bib130","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fimmu.2017.01773","article-title":"The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide","volume":"8","author":"Shaim","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cyto.2018.08.030","article-title":"Src promotes anti-inflammatory (M2) macrophage generation via the IL-4\/STAT6 pathway","volume":"111","author":"Hu","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.leukres.2024.107531_bib132","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor","volume":"23","author":"Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107531_bib133","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-22-2386","article-title":"Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model","volume":"29","author":"Chen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2024.107531_bib134","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/bloodadvances.2020001584","article-title":"PI3K\u03b4 inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax","volume":"4","author":"Serrat","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107531_bib135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2024.107531_bib136","article-title":"SIRP\u03b1 Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2024.107531_bib137","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2024.107531_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:46:25Z","timestamp":1722973585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":136,"alternative-id":["S0145212624000973"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107531","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107531"}}